Building a medtech brand?
We run PR and public affairs for companies in this market: from category launches and funding announcements to NHS procurement and regulatory communications.
Owlstone Medical
Breath biopsy diagnostics
Diagnostics & imaging
Cambridge diagnostics company building breath-based tests, its Breath Biopsy platform, to detect cancer and other diseases from volatile organic compounds on a patient's breath.
The read
Owlstone Medical's Breath Biopsy platform analyses volatile organic compounds in exhaled breath to detect disease non-invasively, targeting lung cancer, liver disease and digestive conditions, and is offered to academic, clinical and pharma partners developing their own breath-based diagnostics rather than sold as a single finished test.
In October 2025 it secured a $49.1m grant from the US government's ARPA-H agency for its POSEIDON programme, developing synthetic-sensor multi-cancer early detection tests capable of screening for more than 30 solid tumours from a single breath sample, alongside a January 2025 Series E first close backed by the Gates Foundation.
The Bridgehead view
Owlstone's pivot toward US federal research funding, an ARPA-H grant nearly double its most recent equity round, is a reminder that for genuinely early-stage diagnostic science, government research money can be a more reliable growth lever than venture capital, and a different PR narrative to tell than a typical funding-round story.
Recent coverage
- Owlstone Medical division and Welbeck Health team up to track digestive condition in the homeBusiness Weekly · 30 Jun 2026
- US breakthrough as Owlstone Medical joins $49m US projectCambridge Independent · 9 Oct 2025POSEIDON - Platform Optimizing SynBio for Early Intervention and Detection in Oncology - adventure for Cambridge company.
- British Owlstone Medical wins ARPA-H award, but will it materialize?European Biotechnology Magazine · 7 Oct 2025Owlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 sol...
FAQs
About this page
No. The MedTech Index is independent editorial coverage — we track and write up companies we judge genuinely significant in the sector, and inclusion is not for sale. Where shown, coverage of Owlstone Medical above is drawn from public reporting, not sponsored content.
We map the sector by who is actually shaping it: funding, product reach, regulatory engagement and the coverage they earn. The MedTech Index is maintained by our editorial team and updated as the market moves, not compiled from vendor submissions.
Yes. If you represent Owlstone Medical, or anything here looks out of date, get in touch through our contact page and we will review it.
Work with us
Working across the healthcare sector?
We advise NHS-facing organisations, providers and health systems on reputation, policy engagement and communications that understand the sector.
Related platforms
Others in the sector map
Cardiology AI (echocardiography)
Ultromics
Oxford spinout building AI software that reads standard echocardiograms to flag hidden heart failure and cardiac amyloidosis, without any extra scanning equipment.
ReadAI pathology platform
Panakeia
Cambridge AI pathology company whose software reads standard tumour tissue slides to deliver molecular cancer profiling in minutes rather than the weeks conventional genomic testing takes.
ReadAI cancer pathology and genomics platform
Sonrai Analytics
Belfast-founded, Queen's University spinout building an AI platform that reads cancer biopsy slides and multi-omic data to support faster, more consistent pathology diagnosis.
ReadRare disease diagnosis AI
Mendelian
AI clinical decision support that scans GP electronic health records to flag patients who may have one of thousands of rare diseases, years earlier than standard care typically catches them.
ReadSelf-test IVD manufacturer
BioSure
Essex-based manufacturer of CE-marked self-test IVDs, best known for producing the world's first CE-marked HIV self-test, sold through UK pharmacies and the NHS.
ReadLateral-flow diagnostics manufacturer
SureScreen Diagnostics
Derby-based, family-run manufacturer of lateral-flow and rapid diagnostic test kits, an NHS supplier since 2010 that produced 20 million UK-manufactured rapid COVID-19 tests for the UK government.
ReadThe firm that knows medtech
We map this sector because
we represent it.
Whether you build medical technology or run the health systems that buy it, we know the market, the media and the regulatory landscape it operates in. Thirty minutes with a partner tells you if we can help.
